Valuation GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.
Stocks
GLAXO
INE159A01016
Pharmaceuticals
|
Market Closed -
NSE India S.E.
15:05:08 17/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 2,799.90 INR | -1.97% |
|
-3.12% | +13.19% |
| 08-03 | GSK India first-quarter profit rises on steady vaccine demand | RE |
| 08-03 | GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: GlaxoSmithKline Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 281,714 | 224,319 | 329,173 | 487,432 | 386,822 | 474,413 | - |
| Change | - | -20.37% | 46.74% | 48.08% | -20.64% | 22.64% | - |
| Enterprise Value (EV) | 256,351 | 207,663 | 329,173 | 487,432 | 386,822 | 474,413 | 474,413 |
| Change | - | -18.99% | 58.51% | 48.08% | -20.64% | 22.64% | 0% |
| P/E | 16.6x | 36.7x | 55.8x | 52.5x | 37.3x | 40.7x | 35.4x |
| PBR | 10.6x | 12.9x | 18.5x | 25x | 17.1x | 17.9x | 15.1x |
| PEG | - | -0.6x | -16.49x | 0.9x | 3.2x | 3.3x | 2.3x |
| Capitalization / Revenue | 8.59x | 6.9x | 9.53x | 13x | 10.1x | 11.1x | 10x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 11.1x | 10x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 32x | 27.8x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 32.3x | 27.7x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 39.5x | 36x |
| FCF Yield | 2.75% | 1.96% | 1.67% | 2.6% | 2.19% | 2.53% | 2.78% |
| Dividend per Share 2 | 30 | 32 | 32 | 42 | 57 | 29.5 | 29.5 |
| Rate of return | 1.8% | 2.42% | 1.65% | 1.46% | 2.5% | 1.05% | 1.05% |
| EPS 2 | 100 | 36.05 | 34.83 | 54.76 | 61.15 | 68.78 | 79.18 |
| Distribution rate | 30% | 88.8% | 91.9% | 76.7% | 93.2% | 42.9% | 37.3% |
| Net sales 1 | 32,780 | 32,517 | 34,537 | 37,492 | 38,217 | 42,568 | 47,241 |
| EBITDA 1 | 8,273 | 8,043 | 9,087 | 11,774 | 13,092 | 14,836 | 17,070 |
| EBIT 1 | 7,592 | 7,385 | 8,390 | 11,106 | 12,428 | 14,698 | 17,112 |
| Net income 1 | 16,947 | 6,107 | 5,900 | 9,276 | 10,360 | 11,654 | 13,418 |
| Net Debt | -25,363 | -16,656 | - | - | - | - | - |
| Reference price 2 | 1,662.95 | 1,324.15 | 1,943.10 | 2,877.30 | 2,283.40 | 2,800.45 | 2,800.45 |
| Nbr of stocks (in thousands) | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | - |
| Announcement Date | 16/05/22 | 17/05/23 | 17/05/24 | 13/05/25 | 13/05/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.35x | 11.76x | 23.85x | 0.61% | 1,014B | |
| 29.73x | 6.61x | 18.52x | 2.01% | 644B | |
| 33.2x | 7.77x | 16.07x | 2.61% | 464B | |
| 19.64x | 4.8x | 11.88x | 2.76% | 354B | |
| 19.71x | 5.15x | 12.77x | 3.12% | 265B | |
| 20.89x | 4.31x | 12.32x | 2.04% | 253B | |
| 23.89x | 6.29x | 11.2x | 2.68% | 203B | |
| 12.12x | 4.42x | 9.24x | 4.14% | 186B | |
| -44.67x | 6.51x | 25.43x | 2.23% | 183B | |
| Average | 16.32x | 6.40x | 15.70x | 2.47% | 396.31B | |
| Weighted average by Cap. | 23.48x | 7.64x | 17.64x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- GLAXO Stock
- Valuation GlaxoSmithKline Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
